Commentary: Clinical Trials Exclude Too Many Patients

By Dr. David Gerber

May 1, 2018. PSA Rising / UT Southwestern Medical Center.
Not long ago, I examined an otherwise healthy and active retiree in his 50s with newly diagnosed metastatic lung cancer. He had no heart disease, no kidney disease, no liver disease. He came to my practice at UT Southwestern Medical Center specifically for clinical trial options.

David Gerber MD
David Gerber, M.D., is associate director for clinical research at the Harold C. Simmons Comprehensive Cancer Center at UT Southwestern Medical Center in Dallas.

Disappointingly, one detail in his medical history excluded him from all of our available trials. Four years earlier, he had been treated for stage 1 prostate cancer, a disease so prevalent and nonaggressive that the U.S. government no longer recommends routine screening for it. I couldn’t think of a single way in which the patient’s prior experience with cancer would interfere with treatments or assessments on a lung cancer trial. And yet I couldn’t enroll him.

Unfortunately, many sick patients are being denied the opportunity to test new drugs that might save their lives. It’s time for this to change. Continue reading “Commentary: Clinical Trials Exclude Too Many Patients”

This month, Prostatepedia focuses on Clinical Trials

This month’s issue of Prostatepedia, a patient-centered prostate cancer publication created and edited by Dr. Charles “Snuffy” Meyers, focuses on clinical trials.

One of the articles featured, “Clinical Trials for Prostate Cancer Patients,” is written by Tony Crispino, Us TOO Las Vegas Support Group Leader and Rick Bangs, bladder and prostate cancer survivor.  Both Tony and Rick serve as research advocates at SWOG and the National Cancer Institute. In their article, they outline the prostate cancer clinical trial process with additional commentary by prostate cancer warrior and clinical trial participant Bob Klingle and his wife Jean.

For the article click:

For the whole May issue click